文献速递临床试验与 GCP

「经验性治疗巨细胞病毒与结核病用于HIV感染重症肺炎婴儿」临床试验的统计分析计划

Statistical analysis plan for the "empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia" clinical trial.
PubMed 文献 · Trials · 2025-04-30

EMPIRICAL试验(NCT03915366)是在六个非洲国家开展的国际多中心II-III期、开放标签、随机析因临床试验,旨在评估经验性抗巨细胞病毒和结核病治疗对比标准治疗对HIV感染重症肺炎住院婴儿不良事件及15天和1年死亡率的安全性和有效性。本文描述该试验的统计分析计划,该计划需在数据库锁定和最终分析结果发布前发表,数据库锁定日期为2025年1月31日。

要点

  • EMPIRICAL试验采用1:1:1:1随机析因设计,比较抗结核治疗、缬更昔洛韦、两者联合与标准治疗。
  • 主要评估指标包括不良事件及15天和1年死亡率。
  • 统计分析计划需在数据库锁定(2025年1月31日)和最终分析结果发布前发表。

核心结论

  • 本文介绍EMPIRICAL试验的统计分析计划,涵盖主要和次要终点的分析细节及待填报表,该计划需在数据库锁定和最终分析结果发布前发表。
  • 数据库锁定日期为2025年1月31日。

研究设计与样本

  • EMPIRICAL试验(NCT03915366)为国际多中心II-III期、开放标签、随机析因临床试验,在六个非洲国家开展。
  • 试验设四个随机分组,按1:1:1:1分配至抗结核治疗联合标准治疗、缬更昔洛韦联合标准治疗、抗结核治疗加缬更昔洛韦联合标准治疗、以及仅标准治疗。
  • 试验注册于ClinicalTrials.gov(NCT03915366,2019年4月16日注册),通用试验编号U111-1231-4736,泛非临床试验注册号PACTR201994797961340。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EMPIRICAL trial aims to assess safety and efficacy of an empirical treatment against cytomegalovirus (CMV) and tuberculosis (TB) compared to standard of care (SoC), on adverse events and 15-day and 1-year mortality among infants living with HIV hospitalized with severe pneumonia in Africa. METHODS AND DESIGN: The EMPIRICAL trial (NCT03915366) is an international multicenter phase II-III, open-label randomized factorial clinical trial conducted in six African countries. The trial has four randomization arms in a 1:1:1:1 fashion with patients allocated to (i) TB-Treatment plus SoC, (ii) valganciclovir plus SoC, (iii) both TB-Treatment and valganciclovir plus SoC, and (iv) SoC only. DISCUSSION: This paper describes the statistical analysis plan (SAP) for the trial which, per the study publication plan, needs to be published prior to the database lock and final analysis results. The SAP includes details of the analyses to be undertaken and unpopulated tables that will be reported to address primary and secondary endpoints. The database will be locked on 31st January 2025. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03915366 (registered on April 16, 2019), Universal Trial Number: U111-1231-4736, Pan African Clinical Trial Registry: PACTR201994797961340.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Domínguez-Rodríguez S, Lora D, Tagarro A, et al. Statistical analysis plan for the "empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia" clinical trial. Trials. 2025. PMID: 40307889. doi:10.1186/s13063-025-08841-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。